[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

[e-drug] Antidiabetic drugs (cont)

  • Subject: [e-drug] Antidiabetic drugs (cont)
  • From: "Dr.L.Offerhaus" <lo@euronet.nl>
  • Date: Wed, 25 Sep 2002 06:08:10 -0400 (EDT)

E-drug: Antidiabetic drugs (cont)

Dear Perla,

On the glibenclamide issue we might decide to agree to disagree. I 
don't believe one word about the alleged direct action of this drug 
on diabetic retinopathy or nephropathy.  If there is one influence, 
it is the strictest control of diabetes possible with any means 
(preferably several injections of insulin over the day), and even 
then successes are few and far between. As to diabetic control: this 
is a group effect of all sulfonamide oral antidiabetics. The only 
difference between glibenclamide and the other drugs is its 
metabolism and pharmacokinetics. So, basically, it is a matter of 
relative availability and price.

As to the insulin issue: In a few years' time 40 U insulin will no 
longer be available. So the main issue is the provision of 
appropriate syringes (or pens) and education.

Best wishes,

Koedijklaan 1a
NL-1406 KW Bussum
The Netherlands
Phone +31-35-6923288 Fax +31-35-6923277
"Dr.L.Offerhaus" <lo@euronet.nl>
To send a message to E-Drug, write to: e-drug@usa.healthnet.org
To subscribe or unsubscribe, write to: majordomo@usa.healthnet.org
in the body of the message type: subscribe e-drug OR unsubscribe e-drug
To contact a person, send a message to: e-drug-help@usa.healthnet.org
Information and archives: http://www.healthnet.org/programs/edrug.html